BRPI0510971A - composto ou um sal farmacologicamente aceitável do mesmo, e, composição farmacêutica - Google Patents

composto ou um sal farmacologicamente aceitável do mesmo, e, composição farmacêutica

Info

Publication number
BRPI0510971A
BRPI0510971A BRPI0510971-0A BRPI0510971A BRPI0510971A BR PI0510971 A BRPI0510971 A BR PI0510971A BR PI0510971 A BRPI0510971 A BR PI0510971A BR PI0510971 A BRPI0510971 A BR PI0510971A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
hydrogen
Prior art date
Application number
BRPI0510971-0A
Other languages
English (en)
Inventor
Yuichi Suzuki
Koichi Ito
Atsushi Sasaki
Koshi Ueno
Miyuki Sakai
Hiroki Ishihara
Atsuhiko Kubota
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BRPI0510971A publication Critical patent/BRPI0510971A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPOSTO OU UM SAL FARMACOLOGICAMENTE ACEITáVEL DO MESMO, E, COMPOSIçãO FARMACêUTICA Compostos representados pela fórmula geral (1) ou sais farmaceuticamente aceitáveis dos mesmos; e o uso dos mesmos como drogas: ¢em que R¬ 1¬ e R¬ 2¬ são substituintes adjacentes e R¬ 1¬ e R¬ 2¬, junto com os dois átomos de carbono, aos quais eles estão Ligados, formam respectivamente um anel hidrocarboneto não-aromático de 5 a 7 membros, que pode ter de um a quatro substituintes selecionados dentre (1) oxo, (2) hidroxila, e assim por diante; R¬ 3¬ é hidrogênio ou similar; e R¬ 6¬ é hidrogênio ou similar!. Os compostos exibem a capacidade de serem combinados com o receptor 5-HT1A e antagonismo para o receptor 5-HT1A e são úteis como agentes terapêuticos ou preventivos contra sintomas do trato urinário inferior, em partir o sintoma de acumulação de urina.
BRPI0510971-0A 2004-05-12 2005-05-11 composto ou um sal farmacologicamente aceitável do mesmo, e, composição farmacêutica BRPI0510971A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004142437 2004-05-12
PCT/JP2005/008632 WO2005108389A1 (ja) 2004-05-12 2005-05-11 ピペリジン環を有するインドール誘導体

Publications (1)

Publication Number Publication Date
BRPI0510971A true BRPI0510971A (pt) 2007-12-04

Family

ID=35310200

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510971-0A BRPI0510971A (pt) 2004-05-12 2005-05-11 composto ou um sal farmacologicamente aceitável do mesmo, e, composição farmacêutica

Country Status (18)

Country Link
US (2) US7538123B2 (pt)
EP (1) EP1757599A4 (pt)
JP (1) JP3902221B2 (pt)
KR (1) KR100788862B1 (pt)
CN (1) CN1984900B (pt)
AU (1) AU2005240928B2 (pt)
BR (1) BRPI0510971A (pt)
CA (1) CA2564062C (pt)
IL (1) IL178940A (pt)
MX (1) MXPA06013034A (pt)
MY (1) MY138420A (pt)
NO (1) NO20065694L (pt)
NZ (1) NZ551024A (pt)
RU (1) RU2332413C1 (pt)
SA (1) SA05260119B1 (pt)
TW (1) TWI391387B (pt)
WO (1) WO2005108389A1 (pt)
ZA (1) ZA200609225B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI391387B (zh) * 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
WO2006082872A1 (ja) * 2005-02-04 2006-08-10 Eisai R & D Management Co., Ltd. １－（ピペリジン－４－イル）－１ｈ－インドール誘導体
EP1880995B1 (en) * 2005-05-11 2011-12-21 Eisai R&D Management Co., Ltd. Method for producing indole derivative having piperidine ring
CN101175751B (zh) * 2005-05-11 2011-03-23 卫材R&D管理有限公司 具有哌啶环的吲哚衍生物的晶体和其制备方法
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
JP5147401B2 (ja) * 2005-09-06 2013-02-20 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
WO2007042325A1 (de) * 2005-10-13 2007-04-19 Morphochem Aktiengesellschaft für kombinatorische Chemie 5-chinolinderivate mit antibakterieller aktivität
JP2008169191A (ja) * 2006-02-20 2008-07-24 Eisai R & D Management Co Ltd 運動ニューロン疾患治療剤
US7541371B2 (en) * 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease
US20100041905A1 (en) * 2006-07-18 2010-02-18 Astrazeneca Ab Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
TW200831140A (en) * 2006-11-28 2008-08-01 Wyeth Corp Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
WO2008101139A1 (en) * 2007-02-16 2008-08-21 Wyeth Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution
TWI410420B (zh) 2008-02-05 2013-10-01 Dainippon Sumitomo Pharma Co 苄基哌啶化合物
US8604189B2 (en) * 2008-05-30 2013-12-10 Emcure Pharmaceuticals Limited Process for the preparation of Efavirenz
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
US8778970B2 (en) 2009-08-04 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd Benzyl piperidine compound
CA2824970C (en) 2011-02-11 2016-05-03 Batmark Limited Inhaler component
TW201326180A (zh) 2011-11-30 2013-07-01 Actelion Pharmaceuticals Ltd ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
AU2014209200B2 (en) * 2013-01-24 2018-11-01 Minerva Neurosciences, Inc. Use of phenoxypropylamine compounds to treat depression
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113717091B (zh) * 2021-09-28 2023-03-10 南京医科大学 一类吲哚衍生物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
US20020193383A1 (en) * 1997-08-01 2002-12-19 Recordati S.A., Chemical And Pharmaceutical Comoany 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring
GB9825413D0 (en) * 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10000739A1 (de) * 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
GB2362381A (en) * 2000-05-18 2001-11-21 Lilly Co Eli Pharmaceutically active indolyl-piperidines
US6844338B2 (en) * 2000-05-18 2005-01-18 Eli Lilly And Company Piperidyindoles as serotonin receptor ligands
MXPA02012927A (es) * 2000-07-21 2003-05-15 Lundbeck & Co As H Derivados de indol utiles para el tratamiento de padecimientos del sistema nervioso central.
JP2002114684A (ja) * 2000-10-03 2002-04-16 Eisai Co Ltd 尿路疾患治療剤
AU2002364590A1 (en) * 2001-12-21 2003-07-30 Eisai Co., Ltd. Hydroxylated indole derivatives and uses thereof
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
TWI391387B (zh) 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
WO2006082872A1 (ja) 2005-02-04 2006-08-10 Eisai R & D Management Co., Ltd. １－（ピペリジン－４－イル）－１ｈ－インドール誘導体
EP1880994A4 (en) 2005-05-11 2010-04-14 Eisai R&D Man Co Ltd INDOLE DERIVED CRYSTAL COMPRISING A PIPERIDINE CYCLE AND PROCESS FOR SYNTHESIZING SAID CRYSTAL
CN101171249B (zh) 2005-05-11 2010-11-10 卫材R&D管理有限公司 制备具有哌啶环的吲哚衍生物的方法
US7541371B2 (en) * 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease

Also Published As

Publication number Publication date
IL178940A (en) 2011-02-28
WO2005108389A1 (ja) 2005-11-17
AU2005240928B2 (en) 2010-08-19
IL178940A0 (en) 2007-03-08
RU2332413C1 (ru) 2008-08-27
CA2564062C (en) 2012-07-10
US7538123B2 (en) 2009-05-26
MY138420A (en) 2009-06-30
CN1984900A (zh) 2007-06-20
ZA200609225B (en) 2008-07-30
TWI391387B (zh) 2013-04-01
CA2564062A1 (en) 2005-11-17
MXPA06013034A (es) 2006-12-20
US20050256103A1 (en) 2005-11-17
KR100788862B1 (ko) 2007-12-27
JPWO2005108389A1 (ja) 2008-03-21
HK1100410A1 (en) 2007-09-21
TW200540174A (en) 2005-12-16
NO20065694L (no) 2007-01-29
KR20070011553A (ko) 2007-01-24
SA05260119B1 (ar) 2008-11-17
AU2005240928A1 (en) 2005-11-17
US20070219179A1 (en) 2007-09-20
EP1757599A1 (en) 2007-02-28
EP1757599A4 (en) 2010-07-14
CN1984900B (zh) 2010-11-10
NZ551024A (en) 2009-06-26
RU2006143769A (ru) 2008-06-20
JP3902221B2 (ja) 2007-04-04

Similar Documents

Publication Publication Date Title
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
BRPI0718714B8 (pt) arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
MY138420A (en) Indole derivative having piperidine ring
BRPI0116607B8 (pt) derivados de glicopiranosiloxipirazol , composições farmacêuticas que os contêm e usos dos mesmos
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
Fernandez-Bolanos et al. Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)
Mallari et al. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB
BRPI0518581A2 (pt) compostos de cromanilurÉia que inibem o receptor do subtipo 1 do recepetor vanilàide (vr1) e usos destes
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
BR0312069A (pt) Compostos de benzimidazol e seu uso como agonistas/antagonistas de estrogênio
MX2012004848A (es) Compuestos heterociclicos triciclicos.
WO2007139815A3 (en) Imaging and therapeutic method using progenitor cells
WO2009054390A1 (ja) チアゾリジンジオン化合物
Motoshima et al. Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists
Leal et al. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
TR200703092A1 (tr) Flurbiprofen ve kas gevşetici kombinasyonları
WO2008074833A3 (en) Compounds
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
WO2010123959A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
Elvir-Lazo et al. Impact of chronic medications in the perioperative period: mechanisms of action and adverse drug effects (Part I)
GT200600455A (es) Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
Jing et al. Combination of chiral linkers with thiophenecarboximidamide heads to improve the selectivity of inhibitors of neuronal nitric oxide synthase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.